ABSTRACT
The combination of abciximab in full doses and reteplase in half doses did not significantly reduce the rate of mortality at 30 days in patients with acute ST-segment elevation myocardial infarction (MI) when compared with reteplase in full doses in the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO V) trial. However, subgroup analysis indicates that the combined regimen reduced the complications of acute MI, representing an important alternative strategy for pharmacologic reperfusion.
Footnotes
↵* The author has indicated that he has received grant/research support from the Centocor and Lilly corporations. This paper discusses treatments that are not approved by the US Food and Drug Administration for the use under discussion.
- Copyright © 2002 The Cleveland Clinic Foundation. All Rights Reserved.